U.S. flag

An official website of the United States government

U.S. Department of Health & Human Services (HHS)
National Institutes of Health (NIH)
OSBR Showcase Categories

Therapeutics

The NIA Small Business Programs support small businesses who aim to develop therapeutic interventions that address factors that impact the aging population, as well as related conditions like Alzheimer’s disease and related dementias.

The small business awardees below were selected by NIH in 2019-2020 to present their groundbreaking technologies and interventions to potential partners and third-party investors at industry showcases.

Displaying 1 - 10 of 11 business showcases.

  • Allyx Therapeutics, Inc.

    Allyx Therapeutics logoRead about Allyx Therapeutics, Inc., a small business using NIA funding to develop an orally bioavailable small molecule that acts as a silent allosteric modulator of metabotropic glutamate receptor 5 in order to slow Alzheimer’s disease progression.

  • AivoCode, Inc.

    AivoCode logoRead about AivoCode, Inc., a small business using NIA funding to develop a therapeutic antibody that neutralizes a novel target, CTGF, which is a hallmark of Alzheimer’s vascular dysfunction and neuroinflammation.

  • Calder Biosciences Inc.

    Calder Biosciences logoRead about Calder Biosciences, a small business using NIA funding to increase the shelf-life of vaccines including the highly contagious respiratory syncytial virus.

  • Cognition Therapeutics, Inc.

    Cognition Therapeutics logoRead about Cognition Therapeutics, a small business using NIA funding to develop therapeutics for Alzheimer’s disease by blocking the action of toxic oligomers on neurons.

  • General Biophysics

    General Biophysics logoRead about General Biophysics, a small business using NIA funding to develop a treatment that is expected to lead to slowing Alzheimer’s disease progression and cognitive decline.

  • Juvena Therapeutics, Inc.

    Juvena logoJuvena Therapeutics, Inc., is a small business using NIA funding to advance a protein therapy for a rare muscle-wasting disease, myotonic dystrophy type 1 (DM1), with an orphan drug status and a more than $40 billion total addressable market (TAM).

  • NeuroEM Therapeutics

    NeuroEM Therapeutics LogoRead about NeuroEM Therapeutics, a small business using NIA funding to develop and commercialize Transcranial Electromagnetic Treatment as a treatment and possible preventative for Alzheimer’s disease and other neurodegenerative diseases.

  • Neurodon, LLC

    Neurodon logoRead about Neurodon, LLC, a small business using NIA funding to develop and deliver first-in-class, disease-modifying medicines to patients with diabetes, neurodegeneration, and other life-threatening diseases.

  • Praxis Bioresearch

    Praxis Bioresearch logoRead about Praxis Bioresearch, a small business using NIA funding to develop safe and effective solutions for the management of behavioral symptoms of Alzheimer’s disease such as apathy.

  • Ridgeline Therapeutics, LLC

    Three green mountains signifying Ridgeline Therapeutics logoRead about Ridgeline Therapeutics, a small business using NIA funding to further the development of small molecule therapeutics for sarcopenia and hip fracture.

nia.nih.gov

An official website of the National Institutes of Health